Therapeutic Use Patents
Defined therapeutic uses of hyaluronidase, including cardiovascular applications
PANTARHIN PHARMA LLC
Advancing Enzyme-Based Therapeutics
Pantarhin Pharma LLC is a U.S. biopharmaceutical company advancing investigational enzyme-based approaches through a structured pharmaceutical development program.
D016 Technology · BELACT® Development · Intellectual Property · Scientific Evidence
Precision
Science
Development
Confidence
Investigational. All programs described on this website are investigational. No product described on this website is approved by the U.S. Food and Drug Administration.
Corporate Positioning
From Technology to Pharmaceutical Development
Pantarhin combines a differentiated enzyme technology with scientific evidence, intellectual property and a disciplined pharmaceutical development strategy.
The company’s current development platform is built around D016, a recombinant hyaluronidase technology, and BELACT®, the lead pharmaceutical development program based on D016.
One technology. One pharmaceutical development program. Defined strategic pathways.
D016 is an investigational recombinant hyaluronidase technology with a designed dual-activity profile combining PH20-like and HYAL4-like enzymatic functions.
Its biochemical characteristics and interaction with extracellular-matrix structures provide the scientific basis for continued preclinical and pharmaceutical development.
D016 is being evaluated within defined development programs and is not positioned as an approved therapeutic product.
Explore D016 TechnologyBELACT® is the lead investigational pharmaceutical development program based on the D016 recombinant hyaluronidase technology.
Its development strategy combines a focused orphan-oriented entry path, with homozygous familial hypercholesterolemia (HoFH) being evaluated as the planned lead indication, and broader cardiovascular development opportunities supported by Pantarhin’s U.S. intellectual-property position.
Development priorities and indication sequencing will depend on scientific evidence, regulatory interaction, clinical feasibility and capital requirements.
BELACT® remains investigational. No specific indication has been approved, and no clinical safety or efficacy has been established.
Explore BELACT® DevelopmentPantarhin’s development strategy is based on the systematic generation and evaluation of scientific evidence.
Research activities focus on the biochemical characteristics of D016, its interaction with extracellular-matrix structures and its investigation in selected preclinical models relevant to cardiovascular development.
Preclinical findings are assessed within their respective experimental context and are used to guide further scientific and pharmaceutical development.
They should not be interpreted as evidence of clinical safety, efficacy or therapeutic benefit.
Science
→
Evidence
→
Development Decisions
Explore Science & Evidence
Intellectual Property
Intellectual Property Supporting Development
Pantarhin’s U.S. intellectual-property position includes issued patents relating to defined therapeutic uses of hyaluronidase, including cardiovascular applications.
This intellectual-property framework is distinct from the D016 technology itself and provides an additional strategic layer supporting focused pharmaceutical development as well as broader cardiovascular development opportunities.
D016 Technology
The recombinant hyaluronidase technology used as the technology basis for pharmaceutical development
BELACT® Development
The lead investigational pharmaceutical development program based on D016
Detailed information regarding patent status, scope and applicable jurisdictions is provided separately.
Development Pathway
A Disciplined Pharmaceutical Development Pathway
Pantarhin follows a staged pharmaceutical development approach in which each step is intended to generate the evidence required for subsequent development decisions.
-
01
Technology Development
D016 characterization, pharmaceutical development and manufacturing readiness
-
02
Preclinical Development
Evaluation of biological activity, pharmacology and safety-related parameters
-
03
Regulatory Strategy & Development
Scientific and regulatory interaction supporting indication prioritization and the design of potential clinical development
-
04
Clinical Development
Potential clinical investigation subject to scientific results, regulatory requirements and applicable authorizations
-
05
Regulatory Review & Potential Approval
Subject to successful completion of the required development program and regulatory review
Progression between development stages is not automatic and depends on scientific findings, regulatory requirements and development decisions.
Investors
Building Value Through Development Milestones
Pantarhin welcomes dialogue with long-term investors and strategic partners interested in supporting the development of investigational enzyme-based therapeutics.
The company’s development strategy is focused on measurable scientific, regulatory and pharmaceutical milestones.
Technology · Evidence · Intellectual Property · Development
Investor-related information is provided on a confidential and case-specific basis.
Pantarhin is a U.S.-focused biopharmaceutical development company advancing investigational enzyme-based pharmaceutical programs.
The company’s current development activities are centered on the D016 recombinant hyaluronidase technology and the BELACT® pharmaceutical development program, including a focused orphan-oriented development path and broader cardiovascular development opportunities.
Pantarhin combines scientific development, intellectual property and regulatory strategy within a structured pharmaceutical development framework.
Pantarhin Pharma LLC is an independent U.S. company working with Pharmact Holding AG, Switzerland, in defined areas of pharmaceutical development, intellectual property, regulatory strategy and partnering.
About Pantarhin Visit PharmactPantarhin Development Platform
Advancing Science Through Disciplined Development
Pantarhin is advancing D016 and BELACT® through an evidence-driven pharmaceutical development framework combining a focused orphan-oriented entry path with broader cardiovascular development opportunities.
D016 Technology · BELACT® Development · Science & Evidence · Intellectual Property
Regulatory Information
The technologies and pharmaceutical programs described on this website are investigational and are intended for scientific, corporate and investor information only.
No product described on this website has been approved by the U.S. Food and Drug Administration. Information concerning preclinical research or potential pharmaceutical applications should not be interpreted as evidence of clinical safety or efficacy, medical advice or promotion of an unapproved product.